United States· US:73362-011_4b962793-361f-4194-8292-af51f5ceaabb
Skytrofa
A lonapegsomatropin product containing lonapegsomatropin, registered in United States by Ascendis Pharma Endocrinology, Inc.. The same ATC class is registered in 8 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Lonapegsomatropin is registered in 8 of 19 countries.
Countries holding a registration under ATC H01AC09 (lonapegsomatropin), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 5 of them publish a price we can compare per daily dose
Lonapegsomatropin · ATC H01AC09
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Ireland
- Netherlands
- Polandprice
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- LONAPEGSOMATROPIN
- Manufacturer
- Ascendis Pharma Endocrinology, Inc.
- Country
- United States (US)
- ATC code
- H01AC09
- ATC class
- Lonapegsomatropin
- Defined daily dose
- 0.9 mg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 1
- ndc1173362-011-01
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lonapegsomatropin in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumSkytrofa 11 mgAscendis Pharma Endocrinology Division
- FinlandSkytrofaAscendis Pharma Endocrinology Division A/S
- NetherlandsSkytrofa 11 mg, poeder en oplosmiddel voor oplossing voor injectie in een patroonAscendis Pharma Endocrinology Division A/S
- PolandSkytrofaAscendis Pharma Endocrinology Division A/S
- SwedenSkytrofa 11 mg Pulver och vätska till injektionsvätska, lösning i cylinderampullAscendis Pharma Endocrinology Division A/S
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Skytrofa
- Liechtenstein · Skytrofa
- Norway · Skytrofa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ae19348d-9c4d-43bf-bc29-e93a00aee5d3 GET /v1/drugs/ae19348d-9c4d-43bf-bc29-e93a00aee5d3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"source": "ndc",
"strength": "13.3",
"substance": "LONAPEGSOMATROPIN",
"productndc": "73362-011",
"dosage_form": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "BLA761177",
"marketing_category": "BLA"
}See everything about lonapegsomatropin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.